ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
52.77
+2.17 (+4.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close50.60
Open50.60
Bid52.15 x 1800
Ask56.10 x 800
Day's Range50.00 - 53.14
52 Week Range34.53 - 96.59
Volume854,824
Avg. Volume543,158
Market Cap1.992B
Beta (3Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-2.05
Earnings DateFeb 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.75
Trade prices are not sourced from all markets
  • Spark Therapeutics (ONCE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
    Zacks4 days ago

    Spark Therapeutics (ONCE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

    Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire4 days ago

    Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 19, 2019, at 8:30 a.m. ET to discuss corporate and financial results for the year that ended Dec. 31, 2018, and recent business highlights. To access a live audio webcast, please visit the “Investors” section of the Spark Therapeutics website at www.sparktx.com. A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 1089969, or by visiting the “Investors” section of the Spark Therapeutics website at www.sparktx.com.

  • This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
    Investor's Business Daily8 days ago

    This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

    Gene therapy player Uniqure could garner takeover interest, an analyst said Friday after the biotech unveiled promising data in hemophilia B. Uniqure rivals Pfizer and Spark Therapeutics.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for ONCE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ONCE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ONCE totaled $2.61 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Gene Therapy: Novartis Under The Microscope With Novel Treatment
    Investor's Business Daily15 days ago

    Gene Therapy: Novartis Under The Microscope With Novel Treatment

    The biotech world is feverishly awaiting the FDA's potential approval of a gene therapy called Zolgensma, a spinal muscular atrophy treatment, that is expected from Novartis in May.

  • Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y
    Zacks16 days ago

    Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y

    Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.

  • GlobeNewswire16 days ago

    Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the presentation of preclinical data for SPK-3006 for Pompe disease and SPK-1001 for CLN2 disease, a form of Batten disease, on Wednesday, Feb. 6, 2019, at the 15th Annual WORLDSymposium™ in Orlando, FL. Giuseppe Ronzitti, Ph.D., team leader at Genethon and researcher at the French National Institute of Health and Medical Research (INSERM), will present preclinical data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease, at 8:45am ET.

  • Calculating The Intrinsic Value Of Spark Therapeutics, Inc. (NASDAQ:ONCE)
    Simply Wall St.24 days ago

    Calculating The Intrinsic Value Of Spark Therapeutics, Inc. (NASDAQ:ONCE)

    How far off is Spark Therapeutics, Inc. (NASDAQ:ONCE) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...

  • Here's What Pushed bluebird bio Stock Down 44.3% in 2018
    Motley Foollast month

    Here's What Pushed bluebird bio Stock Down 44.3% in 2018

    Disappointing drug launches for expensive, single-application treatments poured water on otherwise impressive progress.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ONCE earnings conference call or presentation 9-May-17 12:30pm GMT

    Q1 2017 Spark Therapeutics Inc Earnings Call

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ONCE earnings conference call or presentation 6-Nov-18 1:30pm GMT

    Q3 2018 Spark Therapeutics Inc Earnings Call

  • How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
    Market Realistlast month

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Earnings trends In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

  • How Analysts View Sangamo Therapeutics in December
    Market Realistlast month

    How Analysts View Sangamo Therapeutics in December

    Who Is Eyeing Sangamo Therapeutics Now?Stock performance On December 27, Sangamo Therapeutics (SGMO) stock price closed at $10.59, which is a ~1.58% decline from its prior day close of $10.76 on December 26, 2018.

  • GlobeNewswirelast month

    Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference

    PHILADELPHIA, Jan. 02, 2019 -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic.

  • Novartis (NVS) Benefits From New Drugs & Key Acquisitions
    Zacks2 months ago

    Novartis (NVS) Benefits From New Drugs & Key Acquisitions

    Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.

  • Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer
    Zacks2 months ago

    Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer

    Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.

  • GlobeNewswire2 months ago

    Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated preliminary data on the first 12 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A. These data were presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego by Principal Investigator Lindsey A. George, M.D., assistant professor of pediatrics, The Perelman School of Medicine, University of Pennsylvania and attending physician in the Division of Hematology at Children’s Hospital of Philadelphia. The 12 participants in the Phase 1/2 trial received a single administration of investigational SPK-8011, including two at a dose of 5x1011 vector genomes (vg)/kg body weight, three at a dose of 1x1012 vg/kg and seven at a dose of 2x1012 vg/kg.

  • Spark Therapeutics CEO on breakthroughs in gene therapy
    CNBC Videos2 months ago

    Spark Therapeutics CEO on breakthroughs in gene therapy

    Jeffrey Marrazzo, Spark Therapeutics CEO, joins 'Squawk Box' to discuss how his company is making breakthroughs in gene therapy and the fight to cure hemophilia.